Trial Profile
A Randomized, Double-Blind Phase 3 Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine Plus Placebo For The First-Line Treatment Of Patients With Locally Advanced, Unresectable Or Metastatic Pancreatic Cancer.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs Axitinib (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Pharmacogenomic; Registrational; Therapeutic Use
- Sponsors Pfizer
- 05 Oct 2021 This trial has been completed in France, according to European Clinical Trials Database.
- 02 Jun 2012 Company added in the association field as reported by EudraCT.
- 08 Dec 2011 Status changed from completed to discontinued according to Pfizer and ClinicalTrials.gov description.